The Journal of Medical Investigation
Online ISSN : 1349-6867
Print ISSN : 1343-1420
ISSN-L : 1343-1420
Reviews
Chemoprevention of colorectal cancer
-experimental and clinical aspects-
Tetsuji TakayamaTakahiro GojiTatsuya TaniguchiAtsushi Inoue
Author information
JOURNAL FREE ACCESS

2009 Volume 56 Issue 1,2 Pages 1-5

Details
Abstract

Colorectal cancer is a leading cause of cancer-related mortality worldwide. Therefore, an appropriate prevention strategy should be urgently established. Chemoprevention involves the use of oral agents to suppress the development of cancer. Recent progress in the molecular analysis of colorectal cancer has revealed many candidate molecules for chemoprevention. Many new agents targeting these molecules have also been developed. These agents are largely classified into three categories: 1) Signal transduction modulators including epidermal growth factor (EGF) receptor inhibitors, anti-vascular endothelial growth factor (VEGF) antibodies, and inhibitors of oncogene products. 2) Epigenetic modulators including peroxisome proliferative activated receptor (PPAR)-γ agonists, estrogen receptor (ER)-β, and histone deacetylase inhibitors. 3) Anti-inflammatory modulators including cyclooxygenase (COX)-2, EP 1-4, and NF-kB. Of these agents, some actually proceeded to human clinical trials, and have been shown to be active chemopreventive agents. J. Med. Invest. 56: 1-5, February, 2009

Content from these authors
© 2009 by The University of Tokushima Faculty of Medicine
Next article
feedback
Top